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Abstract
Background: The aim of the present study was to explore the biodistribution, normal tissue toxicity, and
therapeutic efficacy of the internalizing low-dose rate alpha-particle-emitting radioimmunoconjugate
227Th-trastuzumab in mice with HER2-expressing breast cancer xenografts.
Methods: Biodistribution of
227Th-trastuzumab and
227Th-rituximab in nude mice bearing SKBR-3 xenografts were
determined at different time points after injection. Tumor growth was measured after administration of
227Th-
trastuzumab,
227Th-rituximab, cold trastuzumab, and saline. The toxicity of
227Th-trastuzumab was evaluated by
measurements of body weight, blood cell, and clinical chemistry parameters, as well as histological examination of
tissue specimens.
Results: The tumor uptake reached peak levels of 34% ID/g (4.6 kBq/g) 3 days after injection of 400 kBq/kg of
227Th-trastuzumab. The absorbed radiation dose to tumor was 2.9 Gy, while it was 2.4 Gy to femur due to uptake
of the daughter nuclide
223Ra in bone; the latter already explored in clinical phases I and II trials without serious
toxicity. A significant dose-dependent antitumor effect was observed for dosages of 200, 400, and 600 kBq/kg of
227Th-trastuzumab but no effect of 400 and 600 kBq/kg
227Th-rituximab (non-tumor binding). No serious delayed
bone marrow or normal organ toxicity was observed, but there was a statistical significant reduction in blood cell
parameters for the highest-dose group of
227Th-trastuzumab treatment.
Conclusion: Internalizing
227Th-trastuzumab therapy was well tolerated and resulted in a dose-dependent
inhibition of breast cancer xenograft growth. These results warrant further preclinical studies aiming at a clinical
trial in breast cancer patients with metastases to bone.
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Background
Metastatic breast cancer patients have poor prognosis
despite recent therapeutic advances [1]. The human epi-
dermal growth factor receptor-2 (HER-2/neu) is a trans-
membrane receptor tyrosine kinase that is over-expressed
in 25% to 30% of metastatic breast cancers and associated
with more aggressive disease [2]. Trastuzumab (Hercep-
tin
®) is a humanized monoclonal antibody (mAb) directed
against this antigen and shows clinical activity in women
both with HER2/neu-overexpressing primary and meta-
static breast cancer [3].
Tumor cell-targeted alpha emitters have the potential
to improve therapy of hematological malignancies and
micrometastatic disease. Alpha particles have a short
path length (50 to 80 μm) and high linear energy transfer
(LET approximately 100 keV/μm) and, thus, deliver a
high amount of DNA-damaging energy to cells in close
vicinity of their decay. However, no alpha-emitting radio-
immunoconjugate (RIC) has reached phase III clinical
trial yet due to poor physical or chemical characteristics,
supply limitations, and high production costs for the
most promising alpha emitters [4]. Recently, we have
suggested
227Th as a novel radionuclide for alpha-particle
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provided the original work is properly cited.radioimmunotherapy (RIT), as this radionuclide can be
produced in clinically relevant amounts from b-decay of
the long-term generator
227Ac [5,6].
227Ac can be pro-
duced by thermal neutron irradiation of
226Ra in a
nuclear reactor. The yield of
227Ac after purification is
relatively high and
226Ra is highly available, making the
process cost efficient.
227Ac has a half-life of 21.8 years
and thus, would serve as a generator nuclide for
227Th
production for decades [7].
Thorium-227 decays via its alpha- and beta-emitting
daughters
223Ra,
219Rn,
215Po,
211Pb,
211Bi, and
207Tl to
stable 207 Pb. The long half-life of
227Th (T1/2 = 18.7
days) permits the tumor targeting and normal tissue
clearance of a
227Th-labeled RIC to occur before larger
amounts of the daughter nuclide
223Ra is generated.
Upon decay,
223Ra will detach from the antibody. Impor-
tantly, clinical trials have not shown worrisome toxicity
of
223Ra injected as a therapy for prostate cancer bone
metastases [8,9]. Previously, we have shown that
227Th
conjugated to the monoclonal antibody rituximab was
effective in treatment of mice with lymphoma xenografts
and had a relatively low normal tissue toxicity [7,10,11].
The conjugation of trastuzumab with different alpha-
particle-emitting radionuclides, i.e.,
211At,
225Ac, and
213Bi, has already been investigated by other groups
[12-16]. The purpose of the present study was to deter-
mine the biodistribution, therapeutic effect, and toxicity
o ft h el o w - d o s er a t ea l p h a -particle-emitting RIC
227Th-
trastuzumab on HER2-expressing SKBR-3 xenografts. In
vitro experiments have shown internalization of the
227Th-trastuzumab/HER2 complex, retention of
227Th,
and a high toxic effect against single tumor cells [17].
The increased cytotoxic effect created by alpha particles
may offer the opportunity to both improve the overall
response rate of the trastuzumab treatment and also to
treat patients with a lower HER2 expression.
Material and methods
Production of
227Th and radiolabeling of monoclonal
antibodies
227Ac was produced through thermal neutron irradiation
of
226Ra followed by b
- decay of
227Ra (T1/2 =4 2 . 2m i n )
to
227Ac [18].
227Th was selectively retained from a
227Ac decay mixture in 7 M HNO3 by anion exchange
chromatography [19].
Radiolabeling of trastuzumab (Herceptin
®, Hoffmann-
La Roche, Basel, Switzerland) and rituximab (MabThera,
Hoffmann-La Roche) with
227Th was performed at Algeta
ASA, Oslo, Norway. The antibodies were conjugated with
p-SCN-Bn-DOTA at pH 9 (sodium borate buffer) at 37°C
over night. The number of DOTA molecules per anti-
body was approximately four as determined by LC/MS
analysis. The conjugate was purified with a spin filter
(Amicon, Millipore, USA) using 0.9% NaCl as running
buffer removing daughter nuclides and non-chelated
227Th. The purified antibody was distributed to micro-
centrifuge tubes (1 mg/tube) and freeze dried to keep a
larger batch under stable conditions over a long period of
time. The freeze-dried conjugate was dissolved in sodium
acetate buffer pH 5.5 and added about 4 MBq of newly
purified
227Th in 0.01 M HCl. The reaction was done
over night at 42°C in a thermomixer (Eppendorf, Ham-
burg, Germany). The chelate was purified on a NAP5 col-
umn (GE Healthcare, Little Chalfont, UK) using PBS as
running buffer. The specific activity was 1000-1600 kBq/
mg with regard to
227Th.
Immunoreactivity
The immunoreactive fraction (IRF) of the radioimmuno-
conjugate
227Th-trastuzumab was estimated by measur-
ing the cell bound activity in a one point assay. SKOV-3
cells (2 × 10
7 cells/ml) in 200 μlP B Sw e r eu s e d .F o u r
million SKOV-3 cells in one vial of cells were blocked by
incubating with 150 μg/ml cold trastuzumab for 15 min
at 37°C. The cells in another vial were not blocked.
About 500 cpm of
227Th-trastuzumab was added to each
vial and the cells were incubated for 2 h before washing
and measurement of radioactivity with an automated
gamma counter (Wizard, Packard Instrument Co., Down-
ers Grove, IL, USA). IRF was 70% to 90%.
Animals
All procedures and experiments involving animals in this
s t u d yw e r ea p p r o v e db yt h eN a t i o n a lA n i m a lR e s e a r c h
Authority and carried out according to the European Con-
vention for the Protection of Vertebrates used for Scienti-
fic Purposes. The animals were maintained under
pathogen-free conditions. Food and water were supplied
ad libitum. Eight to 12 weeks old, institutionally bred
female Balb/C nu/nu (NCR) mice, with an average weight
of 20 to 27 g at the start of study, were used. Mice were
anesthetized with subcutaneous injection of 0.05 ml Zole-
til
® mix (Virbac, Carros Cedex, France) before HER-2-
positive breast cancer (SKBR-3) tumor fragments from
xenografted animals (1 × 1 × 1 mm) were implanted
subcutaneously. The xenografted tumor line originated
from HER-2-positive breast cancer (SKBR-3) cells from
American Type Culture Collection (Manassas, VA). Mice
with growing tumors of diameters between 4 and 8 mm
were included in the experiments. Mice were killed by cer-
vical dislocation.
Biodistribution of
227Th-labeled antibodies
The conjugates
227Th-trastuzumab and
227Th-rituximab
were administered by tail vein injection of 100 μl (15 kBq)
solution to each animal. For each conjugate and time
point, a total of four to six animals were autopsied. Tumor
and organs were measured for radioactivity content and
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references in the measurement procedure.
Thorium-227 and
223Ra were measured using a solid-
state photon well detector (GCW6021, Canberra, Meridan,
CT, USA) coupled to a digital gamma ray spectrometer
and analyzed using the computer software Apex™ version
1 (Canberra). For
227Th, the 236 keV (abundance 17.6%)
and 256 keV (abundance 9.5%) g-ray lines were used and
for
223Ra the 154 keV (abundance 5.7%), 269 keV (abun-
dance 13.9%), 324 keV (abundance 4%), and 338 keV
(abundance 2.8%) g-ray lines were used.
Calculation of absorbed dose
The total number of disintegrations, i.e., the cumulated
activity, in various tissues from the time of injection of
the preparation until no activity was left in the body was
estimated by calculation of the area under the activity
concentration versus time curves (AUC). For
227Th-
labeled antibodies, the absorbed radiation doses were cal-
culated assuming dose contributions coming only from
a-particle emissions with a mean a-energy (Ea)o f5 . 9
MeV for
227Th and 26.4 MeV for
223Ra with its daughters
in equilibrium, and that there was a 100% absorption of
the absorbed dose from the a-particle within a tissue, i.e.,
absorbed fraction equal to unity (ø =1 ) .F o ra-particle
radiation uniform distribution of radionuclides in the
various tissues as well as no cross irradiation was
assumed. Thus, the total absorbed dose to each organ
was estimated by: Dose = AUC0
∞ ·E a (
227Th) + AUC0
∞ ·
Ea (
223Ra + daughters). Also for blood, the absorbed dose
was calculated assuming 100% absorption of the a-parti-
cles, i.e., ø = 1. This was obviously a simplification since
in the capillaries there will probably be escape of a-parti-
cles beyond the blood.
Therapeutic studies
Mice were injected with a single dose of NaCl (control;
n =1 0 ) ,2 0μg( n =5 ) ,1 0 0μg( n =6 ) ,o r2 5 0μg( n =5 )
of cold trastuzumab; 200 kBq/kg (n = 10), 400 kBq/kg (n
=1 1 ) ,a n d6 0 0k B q / k g( n =1 2 )o f
227Th-trastuzumab;
and 400 kBq/kg (n =9 )a n d6 0 0k B q / k g( n =1 0 )
227Th-
rituximab in 100 μl solution. Tumor growth and mouse
weight were assessed three times a week in the first week
before injection and the 3 weeks after injection; there-
after, weight, growth, and survival were assessed twice a
week. Caliper measurements of perpendicular tumor dia-
meters were used to estimate tumor volume by assuming
ellipsoid shape. Mice with tumor diameter larger than
20 mm were killed. Mantley Cox log rank test was used
to test for significant differences in surviving fraction of
mice, which is defined as the fraction of mice that did
not have to be sacrificed due to tumor diameter above
20 mm.
Evaluation of toxicity
Toxicity was evaluated in all treatment groups except
227Th-rituximab. Approximately 100 to 200 μlo fb l o o d
was collected from the vena saphena lateralis in 500 μl
EDTA-coated tubes (Microtainer K2E tubes, Becton,
Dickinson, NJ, USA) for blood cell counting. Blood sam-
ples were taken before and at 3, 6, and 8 to 10 weeks after
start of the study. For control, a group of ten mice without
tumor was injected with NaCl and sampled at the same
time points for blood cell count. While for clinical chemis-
try data, the samples from this control group were taken
after 8 weeks. Blood cells were counted in an automatic
blood counter (Scil Vet ABC, Horiba ABX, Montpellier,
France). In addition, when mice were sacrificed due to
tumor size or weight loss, blood samples were collected by
heart puncture into EDTA-coated tubes and also lithium
heparin-coated tubes (Microtainer LH tubes, Becton,
Dickinson) for analysis of clinical chemistry parameters.
Clinical chemistry strips were used to assess the serum
aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), alkaline phosphatase (ALP), and urea level
(Reflotron, Roche Diagnostics GmbH, Mannheim,
Germany). Full blood samples (30 μl) were analyzed by a
clinical chemistry analyzer (Reflovet, Roche Diagnostics).
At the end of the study, the lung, heart, kidney, spleen,
small intestine, large intestine, liver, femur, skull, and
tumor were fixed with formalin, cut in 5-μm slices, stained
with hematoxylin and eosin, and analyzed by a pathologist
to detect any pathological changes. Slides from cold trastu-
zumab and
227Th-trastuzumab groups were compared to
the slides of control groups.
Autoradiography
Mice bearing tumor xenografts were injected with 15 kBq
of
227Th-trastuzumab, corresponding to approximately
600 kBq/kg. Four animals were sacrificed by cervical
dislocation 4 and 8 days after injection. Tumors were
removed and immediately frozen in liquid nitrogen.
Tissue sections of thickness 5 μm were used for exposure
of Kodak Biomax MR-1 single-sided emulsion or Kodak
Medical General Purpose Blue x-ray film (Eastman
Kodak Company, Rochester, NY, USA). Films were
exposed for 6 to 11 days at -80°C prior to development.
Film patterns were compared to hematoxylin and eosin
(H/E)-stained tissue sections.
Results
Biodistribution and dosimetry of
227Th -trastuzumab and
227Th-rituximab
The in vivo biodistribution profiles of
227Th-trastuzu-
mab,
227Th-rituximab, and the daughter nuclide
223Ra in
nude mice with SKBR-3 xenografts at different time
points after administrationa r es h o w ni nF i g u r e1 .T h e
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Page 3 of 12maximum uptake of
227Th-trastuzumab in tumor
(4.6 kBq/g) occurred 3 days after injection (Figure 1a).
There was a large difference between the amount of
activity in tumor and in normal organs for
227Th-trastu-
zumab. The uptake of non-tumor binding
227Th-rituxi-
mab (Figure 1b) in tumor was significantly lower than
the uptake of
227Th-trastuzumab (Figure 1a). The
227Th
daughter nuclide
223Ra was mainly localized to bone
(femur and skull) but there were also some retention of
223Ra in spleen, kidneys, and in tumor (Figure 1c, d).
The absorbed radiation dose in tumor was 2.9 ± 0.8 Gy
for
227Th-trastuzumab (Figure 2a) and 0.7 ± 0.1 Gy for
227Th-rituximab (Figure 2b); both normalized to injections
of 400 kBq/kg. Radiation doses were less than 2 Gy for all
organs for both RICs, except for femur (2.4 ± 0.6 Gy) and
skull (2.7 ± 0.6 Gy) in mice treated with
227Th-trastuzumab.
Therapeutic efficacy
Growth of SKBR-3 tumor xenografts in mice treated
with alpha-particle-emitting
227Th-trastuzumab was
compared with cold trastuzumab, non-tumor binding
227Th-rituximab, as well as saline (controls; Figure 3).
There was a large variability in tumor growth within
treatment groups. Table 1 shows growth delays calcu-
lated from average tumor growth curves. The mean
tumor growth in mice treated with cold trastuzumab
(20, 100, and 250 μg/mice or approximately 0.8, 4, and
10 mg/kg body weight) or 400 and 600 kBq/kg
227Th-
rituximab was similar to the growth of the untreated
controls. The dosage groups for cold trastuzumab and
for
227Th-rituximab in Table 1 and Figure 3b, c were
pooled since there was no difference between them. For
200 and 400 kBq/kg
227Th-trastuzumab, some of the
tumors responded well to the treatment, while others
did not (Figure 3d, e). The average delays to grow to a
normalized tumor volume of 500 mm
3 were 7 and
23 days, respectively (Table 1). For 600 kBq/kg
227Th-
trastuzumab, all tumors responded to the treatment
(Figure 3f) and the average growth delay to reach a
tumor volume of 500 mm
3 was 45 days (Table 1).
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Figure 1 Biodistribution of
227Th-conjugates and
223Ra in mice with SKBR-3 xenografts. Biodistribution profile of
227Th-trastuzumab (a) and
daughter nuclide
223 Ra (c) after administration of
227Th-trastuzumab, and biodistribution of
227Th-rituximab (b) and daughter nuclide
223 Ra (d)
after administration
227Th-rituximab, in mice bearing SKBR-3 xenografts. The measured
227Th activities were normalized to an injection of 400
kBq/kg bodyweight. Values are mean ± SD. N = 6 for each time point except at day 3, where N =5 .
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Page 4 of 12The surviving fraction of the different dosages of
227Th-
trastuzumab was not significantly different from each
other (p > 0.05), but there was a significant difference in
survival between the
227Th-trastuzumab treatment groups
and control groups (NaCl and trastuzumab; p < 0.001)
(Figure 4a). Mean and median survival times were signifi-
cantly different for mice in the dosage groups 400 and
600 kBq/kg
227Th-trastuzumab as compared to mice in
the NaCl (control) group (p < 0.05; Table 2). None of the
dosages of cold trastuzumab had an effect on survival (p =
0.40). Hence, the data were pooled into one group. The
survival of mice treated with non-tumor-binding
227Th-
rituximab was not significantly different from the survival
of the control group (p > 0. 6; Figure 4b). In addition, no
significant differences (p > 0.05) in mean and median sur-
vival times between control and
227Th-rituximab treat-
ment groups were observed (Table 2).
Toxicity of
227Th-trastuzumab
White blood cell (WBC), platelet cell (PLT) counts, and
clinical chemistry parameters of control mice and mice
treated with
227Th-trastuzumab are shown in Figures 5
and 6. Figure 5a, b shows WBC and PLT counts of indivi-
dual mice as well as mean values at 0, 3, 6, and 9 weeks
time points from each treatment groups. In the control
groups mice without tumor was also included in order to
g e tm e a s u r e m e n t sa tl o n g e rf o l l o w - u p .T h eW B Cc o u n t
was significantly lower in the control (NaCl) group at
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Figure 2 Absorbed radiation doses to normal tissues and tumor xenografts. Absorbed radiation dose in tumor and normal organs of mice
injected with
227Th-trastuzumab (a)o r
227Th-rituximab (b). Cumulated activities were calculated from biodistribution curves and multiplied with
the mean energy of a-particles from
227Th,
223Ra, and daughters. Biodistribution data of
227Th-trastuzumab and
227 Th-rituximab were normalized
to 400 kBq/kg bodyweight.
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Page 5 of 12time 0 as compared to 3 weeks after injection. WBC
decreased significantly for treatment with 400 kBq/kg (p
<0 . 0 0 1 ,t test) and 600 kBq/kg (p < 0.001, t test) of
227Th-trastuzumab as compared to WBC in the cold tras-
tuzumab group and control mice after 3 weeks (Figure
5 a )b u tn o ta sc o m p a r e dw i t ht h e0t i m ep o i n t .A f t e r6
weeks, only the 600 kBq/kg
227Th-trastuzumab group
was significantly different from control (p = 0.008, t test).
N os i g n i f i c a n td i f f e r e n c ei nP L Tc o u n tw a sf o u n df o r
the 200 kBq/kg
227Th-trastuzumab treatment group
when compared to control at any time point (Figure 5b).
The PLT count was significantly lower for the 400 kBq/
kg (p = 0.017, t test) and 600 kBq/kg (p = 0.003, t test)
227Th-trastuzumab treatments as compared to control
after 3 weeks. At 6 weeks, the PLT counts had recovered.
However, at 9 weeks, the PLT count was significantly
A                          
T
u
m
o
r
 
V
o
l
u
m
e
 
(
m
m
3
)
0
1000
2000
3000
4000 B                         
D                        
E
Time after injection (days)
0 2 04 06 08 0 1 0 0
T
u
m
o
r
 
V
o
l
u
m
e
 
(
m
m
3
)
0
1000
2000
3000
4000 F                            
Time after injection (days)
0 2 04 06 08 0 1 0 0
  C
T
u
m
o
r
 
V
o
l
u
m
e
 
(
m
m
3
)
0
1000
2000
3000
4000
Figure 3 Effects of
227Th-based RIT on growth of individual SKBR-3 tumor xenografts. Individual tumor growth after treatment with NaCl
(a); 20, 100, and 250 μg cold trastuzumab (b);
227Th-rituximab at dosage of 400 and 600 kBq/kg (c); 200 kBq/kg (d); 400 kBq/kg (e) and 600 kBq/
kg (f)o f
227Th-trastuzumab. N = 9 to 19.
Table 1 Growth inhibition for tumor volume of 500 and 1,000 mm
3 after treatment
Treatment Dosage 500 mm
3 1,000 mm
3
Days
a Growth delay
b Days Growth delay
NaCl 15 ± 7 0 ± 10 25 ± 7 0 ± 11
Trastuzumab (pooled) 20 - 250 μg1 5 ± 70 ± 1 1 2 3 ± 8- 2 ± 1 2
227Th-rituximab 400 and 600 kBq/kg 15 ± 8 -3 ± 11 27 ± 10 2 ± 11
227Th-trastuzumab 200 kBq/kg 22 ± 8 7 ± 11 32 ± 8 7 ± 12
227Th-trastuzumab 400 kBq/kg 38 ± 8 23 ± 10 70 ± 10 45 ± 12
227Th-trastuzumab 600 kBq/kg 60 ± 7 45 ± 7 90 ± 10 65 ± 7
aThe number of days to reach the chosen tumor volume.
bGrowth delay = days (treatment) - days (NaCl).
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Page 6 of 12lower than the control for the 400 kBq/kg
227Th-trastu-
zumab group (p = 0.038, t test) and for the cold trastuzu-
mab group (p < 0.001, t test) as compared to control
mice.
Urea, AST, ALT, and ALP levels in blood from control
mice were compared with blood from mice treated with
cold trastuzumab, 200, 400, and 600 kBq/kg of
227Th-
trastuzumab (Figure 6a, b, c, d). Urea levels were within
the normal range and were not significantly different
from control. One mouse in each RIT group and one
control mouse showed high ALT levels, i.e., above nor-
mal range. Another mouse treated with 200 kBq/kg
227Th-trastuzumab group had a very high AST levels as
compared to mice in all other treatment groups. Large
variations in ALP levels were observed among all treat-
ment groups but were within the normal range. Therapy
related pathological changes were not observed in any
organ upon histological examination.
Figure 7 shows no morphological differences in normal
bone marrow for a mouse treated with NaCl (Figure 7a)
and a mouse treated with 600 kBq/kg of
227Th-
trastuzumab up to 72 days (Figure 7b). Body weights of
animals were measured throughout the study but no sig-
nificant differences between the treatment groups were
observed (data not shown).
Autoradiography
Autoradiography of SKBR-3 tumor xenografts showed
that the distribution patterns of radioactivity after injec-
tion of 600 kBq/kg of
227Th-trastuzumab were inhomo-
geneous (Figure 8). The smallest of the tumors analyzed
showed highest concentration of radioactivity present as
a rim corresponding to areas with viable tumor tissue
close to the well perfused connective tissue capsule sur-
rounding the tumor (Figure 8a). The tumor in Figure 8b
had localized hotspots. On the corresponding H/E-
stained tissue section, the hotspots with high
227Th-tras-
tuzumab uptake matched areas with high density of
blood vessels and/or large blood vessels, with areas of
necrotic tissue and loosely bound cells in between. A
similar correspondence was also seen in tissue sections
taken at later time points (Figures 8c, d).
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Figure 4 Effects of
227Th-based RIT on survival of mice with SKBR-3 tumor xenografts. Survival of mice after intravenous injection of NaCl,
20,100, and 250 μg cold trastuzumab, and 200, 400, and 600 kBq/kg
227Th-trastuzumab (a), or 400 and 600 kBq/kg
227Th-rituximab (b).
Table 2 Mean and median survival times for all treatment groups
Treatment Dosage Mean ± standard error Median ± standard error Number of mice
NaCl 52 ± 10 42 ± 13 10
Trastuzumab (Pooled) 20 - 250 μg 5 4±5 4 7±2 1 6
227Th-rituximab 400 kBq/kg 44 ± 5 49 ± 8 9
227Th- rituximab 600 kBq/kg 47 ± 5 36 ± 3 10
227Th-trastuzumab 200 kBq/kg 39 ± 2 38 ± 2 10
227Th-trastuzumab 400 kBq/kg 87 ± 7* 63 ± 3* 11
227Th-trastuzumab 600 kBq/kg 95 ± 3* 96 ± 3* 12
*Significant difference between control and therapy.
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The present study of alpha-particle-emitting
227Th-tras-
tuzumab showed a significant dose-dependent inhibition
of tumor growth of human SKBR-3 breast cancer xeno-
grafts in mice, leading to long-term survival with low
toxicity.
In RIT with
227Th the distribution of free daughter
nuclides also has to be considered, as the daughter nuclide
223Ra detaches from the DOTA-trastuzumab construct
upon alpha-particle emission from
227Th. The biodistribu-
tion study showed that
223Ra re-localized to bone and to
spleen. It should be noticed that the 18.7-day half-life of
227Th allows for excretion of a large fraction of
227Th-
trastuzumab before
223Ra is formed. The uptake in spleen
was probably related to mouse-specific calcification of the
spleen [20]. Radium-223 has a half-life of 11.4 days and is
excreted from the blood via the intestines with a major
part of the
223Ra ending up in the hydroxyapatite of bone
[8,20,21]. The half-lives of the
223Ra-daughters are in the
millisecond to minute range. They are therefore likely to
contribute mainly to the absorbed radiation dose in
the vicinity of the site of
223Ra decay. Thus, as shown in
Figure 2 the absorbed doses to bone were comparable to
the doses in tumor.
Microautoradiography studies of
227Th-rituximab have
shown that there probably is a contribution to the bone
marrow absorbed dose from
223Ra and daughters on the
bone surface [11]. One could suspect that localization in
bone would give a high contribution to bone marrow
toxicity, but clinical studies of
223Ra have shown that it
is well tolerated by breast and prostate cancer patients
[8], with data from repeated dosing suggesting no more
damage on red bone marrow compared to placebo [9].
This lack of toxicity is probably due to the short path
length of alpha emission, as previous data have shown
that the beta-emitter strontium-89 is strikingly more
toxic, although presumably localizing in an identical way
in bone tissue [20]. Therefore, we suggest that localiza-
tion of small amounts of
223Ra in bone tissue would be
acceptable. Furthermore, because of the long half-life of
227Th and internalization of HER-2 antigen after binding
to
227Th- trastuzumab complex much of the
227Th will
be excreted or internalized before
223Ra is formed and
thereby reducing relocalization of
223Ra to bone. We
also suggest that an optimized chelator will reduce the
small amounts of free
227Th, indicated by the present
biodistribution data.
No severe bone marrow toxicity was observed in this
study even when therapeutically effective amounts were
administered. A dosage of 600 kBq/kg of
227Th-rituximab
is equal to an absorbed radiation dose in tumor of
around 1 Gy. One could expect a small therapeutic effect
of this dose since there was a significant therapeutic
effect of 200 kBq/kg (1.45 Gy) of
227Th-trastuzumab.
However, there was no therapeutic effect of even the
highest dosage of
227Th-rituximab, showing that the anti-
body has to bind to the cells to get the emitted alpha par-
ticles close enough to the tumor cell nucleus. This is in
analogy with the lack of bone marrow toxicity, discussed
above, i.e., the low bone marrow toxicity might be due to
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Figure 6 Assessment of liver and kidney functions after
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Figure 7 Histological examination of bone marrow after
227Th-trastuzumab therapy. Histological microscopy images of bone marrow in
femur of mice after administration of NaCl (a) or 600 kBq/kg
227Th-trastuzumab (b) showing islands of haemopoetic cells composed of blood
cells in various stages of maturation (arrow a), a great population of nucleated blood cells (arrow b), and blood vessels (arrow c).
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227Th-trastuzumab or
223Ra to
bone marrow cells.
In the present study, the tumor volumes were 8 to 16
times larger than the size of micrometastases (< 2 mm
in diameter) in breast cancer patients. However, in a
previous study we treated single SKBR-3 cells and
achieved up to two log reduction in clonogenic survival
and growth inhibition [17]. Therefore, one relevant clin-
ical setting for
227Th-trastuzumab might be adjuvant
treatment of breast cancer patients with micrometas-
tases. Due to the
223Ra (daughter) affinity to bone,
patients with a high risk of developing bone metastasis
might be an intriguing application [22,23].
There was a dosage-dependent increase in tumor
growth inhibition but not for survival. This may be
related to individual differences in tumor vascularization
and the presence of necrosis. In the 200 kBq/kg group we
observed a variable therapeutic effect, while in the 400
and 600 kBq/kg groups we got a more prominent and
similar therapeutic effect.
Radiolabeled antibody therapy for solid tumor has been
less successful as compared to hematological tumors. The
A C
B
D
Figure 8 Autoradiography images after
227Th-trastuzumab therapy. Autoradiography images of the radioactivity distribution in 5-μm-thick
frozen tissue sections from four different SKBR-3 human tumor xenografts in athymic nude mice following injection of 600 kBq/kg of
227Th-
trastuzumab. Tumors in mages (a) and (b) were resected 4 days post injection, while (c) and (d) were removed 8 days post injection. N =4 .
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to radiation and are more difficult to target due to macro-
molecule transport barriers, e.g., vascular supply limitation,
high interstitial pressure, and vascular permeability limita-
tion. Targeted delivery of high LET a-particles after
administration of
227Th-trastuzumab may not be the only
reason behind the successful growth inhibition of SKBR-3
tumor xenografts. The autoradiography images indicated
that
227Th-trastuzumab in some tumors, were located close
to the tumor vasculature. Targeting the tumor vasculature
or vasculature near the tumor cells with a-emitting radio-
nuclides has previously been shown to yield a therapeutic
effect on solid tumors [24,25].
The tumors treated in the present study were much
larger than the range of alpha particles. However, the
autoradiogaphy images indicated hot spots of
227Th-tras-
tuzumab activity in perfused areas within the tumor
xenografts, which might result in destruction of the
blood vessels and eradication of tumors due to lack of
nutrients. Furthermore, there was also some retention of
free
223Ra in tumor. This is a small ion with several a-
emitting daughter radionuclides that might surmount the
macromolecular transport barriers of solid tumors and
result in high LET a-irradiation of tumor cells not
reached by the larger molecule
227Th-trastuzumab. Thus,
the antitumor effect might have been a combined effect
of tumor cell kill by both
227Th-trastuzumab,
223Ra, and
daughters and destruction of the blood vessels that deli-
vers nutrients and oxygen to the tumor cells.
At two samplings, the dosage-dependent decrease in
the WBC count was significantly lower for mice in one
or both of the two highest dosages groups compared to
control mice; both for the 400 and 600 kBq/kg
227Th-
trastuzumab groups at 3 weeks after injection, and for
the 600 kBq/kg
227Th-trastuzumab at 6-week time
points. However, the blood values were within the nor-
mal physiological range for nude mice for all dosages of
227Th-trastuzumab. Furthermore, the most striking
change in the WBC count is the increase for the control
group from 0 to 3, 6, and 9 weeks. If the WBC count at
3, 6, and 9 weeks are compared with the WBC count of
the control at 0 weeks there is no significant difference.
The reason for this increase is unknown, but it might be
related to an undetected infection in one cage of the
control mice. Therefore, we conclude that the
227Th-
trastuzumab treatment had no pathological effect on the
WBC count.
There was a dosage-dependent decrease in PLT count
at 3 weeks after injection, but the PLT count had recov-
ered after 6 weeks. At the 9-week time point, the PLT
count was significantly lower than the control for the
400 kBq/kg
227Th-trastuzumab group and the cold tras-
tuzumab group. However, this decrease was probably
related to a combination of biological variation and the
low number of mice in these two groups (5 and 1, respec-
tively). It should also be pointed out that control mice
without tumor xenografts were used in order to get
blood samples for the controls at the later time points.
Liver enzymes and urea levels in the blood did not
show any dose-dependent changes following injection of
227Th-trastuzumab with levels in the highest dosage
group similar to that of control. Other treatment groups
showed random increase or decrease of some enzymes
when compared with control. This may be related to
one mouse within each group with very high value of
the parameter in question. Since there were no dose-
dependent changes and since there were no significant
changes between the control and the 600 kBq/kg group
for any parameters, these changes might be due to other
factors than the
227Th-trastuzumab treatment.
In conclusion,
227Th-trastuzumab inhibits growth of
breast cancer xenografts in a dose-dependent manner.
Possibly due to the longer half-life, single dosing was effi-
cacious; not excluding that improved efficacy might be
obtained with multiple doses, as has been shown clini-
cally with a more short-lived alpha emitter [9]. The lim-
ited toxicity of the treatment was mainly related to
reversible bone marrow depression. Further preclinical
studies of
227Th-trastuzumab involving mice with breast
cancer micrometastases and, if possible, metastasis to
bone are warranted.
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